The American Journal of Medicine
Volume 122, Issue 1, Supplement , Pages S3-S14 , January 2009

The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment

  • William Insull Jr., MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to William Insull, Jr., MD, Lipid Research Clinic, Baylor Faculty Center, 1709 Dryden Road, Suite 08.08, Houston, Texas 77030-3411

References 

  1. McGill HC. The geographic pathology of atherosclerosis. Lab Invest. 1968;18(theme issue):465–653
  2. Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 1990;11(suppl E):3–19
  3. Shattock SG. A report upon the pathological condition of the aorta of King Menephtah, traditionally regarded as the Pharaoh of the Exodus. Proc R Soc Med. 1909;2(Pathol Sect):122–127
  4. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007;13:719–724
  5. Deguchi JO, Aikawa M, Tung CH, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114:55–62
  6. Rosenfeld ME, Schwartz SM. The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management. In:  Virmani R,  Narula J,  Leon MB,  Willerson JT editor. Murine models of advanced atherosclerosis. Malden, MA: Blackwell Publishing; 2007;p. 105–127
  7. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488
  8. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(suppl 1):II2–II10
  9. Paoletti R, Gotto AM, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(suppl 1):III20–III26
  10. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876–1890
  11. Stary HC. Atlas of Atherosclerosis: Progression and Regression. 2nd ed.. New York: Parthenon Publishing Group; 2003;
  12. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–1275
  13. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103:934–940
  14. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281:727–735
  15. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY study. Arterioscler Thromb. 1993;13:1291–1298
  16. Eggen DA, Solberg LA. Variation of atherosclerosis with age. Lab Invest. 1968;18:571–579
  17. Cheruvu PK, Finn AV, Gardner C, et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol. 2007;50:940–949
  18. Moreno PR, Purushothaman KR, Zias E, Sanz J, Fuster V. Neovascularization in human atherosclerosis. Curr Mol Med. 2006;6:457–477
  19. Ibañez B, Badimon JJ, Garcia MJ. Diagnosis of atherosclerosis by imaging. Am J Med. 2008;122(suppl):S15–S25
  20. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–1374
  21. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab Invest. 1968;18:509–526
  22. International Atherosclerosis Project. General findings of the International Atherosclerosis Project. Lab Invest. 1968;18:498–502
  23. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343:915–922
  24. Schoenhagen P, Stone GW, Nissen SE, et al. Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arterioscler Thromb Vasc Biol. 2003;23:1895–1900
  25. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004;110:278–284
  26. Bays HE. “Sick fat,” metabolic disease, and atherosclerosis. Am J Med. 2008;122(suppl):S26–S37
  27. Lewis SJ. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. Am J Med. 2008;122(suppl):S38–S50
  28. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  30. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT): major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998–3007
  32. Crouse JR, Raichlen JS, Riley WA, et al. METEOR Study Group Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007;297:1344–1353
  33. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005;46:106–112
  34. Underhill HR, Yuan C, Zhao HQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008;155:584.e1–584.e8
  35. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  36. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565
  37. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508
  38. Saam T, Yuan C, Chu B, et al. Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis. 2007;194:e34–e42
  39. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20–28
  40. Insull W. Effects of statin treatment for regression of carotid atherosclerosis: a literature review of clinical trials analyzing carotid plaques by histopathology. J Clin Lipidol. 2007;1:371;Abstract 134
  41. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 2003;91(suppl 4A):4B–8B
  42. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  43. Ray KK, Cannon CP, McCabe CH, et al. PROVE IT–TIMI 22 Investigators Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405–1410
  44. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL studyA randomized controlled trial. JAMA. 2001;285:1711–1718
  45. Schwartz G, Singh D. Intensive statin therapy reduces clinical events at 30 days and after six months in acute coronary syndromes. Evid Based Cardiovasc Med. 2006;10:35–37
  46. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, et al. West of Scotland Coronary Prevention Study Group Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–1486
  47. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in the Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  48. Shepherd J. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics. Atherosclerosis Suppl. 2007;8:9–12

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 To access a slide kit for this article, please click here.

PII: S0002-9343(08)01017-6

doi: 10.1016/j.amjmed.2008.10.013

The American Journal of Medicine
Volume 122, Issue 1, Supplement , Pages S3-S14 , January 2009

Article Tools

* Image Usage & Resolution